Think your needle is stuck in a rut on that record Steini.
There are several biotechs that seem to be well undervalued on the ASX, and a couple of ex dogs of the market that hAve made substantial moves (most of those in far earlier stages of development, and one drug only when compared to CHM).
CHM has proof they may have the first CarT to work against a solid tumour cancer. They have extended the lives of past heavily treated GBM patients beyond statical norms. And thats just one of the drugs. That drug has now progressed to a level two treatment in the expanded phase 1b trial. So hopefully these results can be improved upon now its hitting the arm of a healthier patient.
Keep on doing ya stuff CHM team. Its a tough market at the moment. But if these results can be replicated or improved upon the share price will take care of itself.
Its a welcome change to finally see some volume happening here. A much healthier environment for all holders when that happens.
CHM Price at posting:
3.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)